Prospective Trial Incorporating Pre-/Mid-Treatment [18F]-Misonidazole Positron Emission Tomography for Head-and-Neck Cancer Patients Undergoing Concurrent Chemoradiotherapy

International Journal of Radiation Oncology Biology Physics

Volumn 75, Issue 1, 2009, Pages 101-108

  Lee, Nancy ^a   Nehmeh, Sadek ^a   Schöder, Heiko ^a   Fury, Matthew ^a   Chan, Kelvin ^a   Ling, C Clifton ^a   Humm, John ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

18F FMISO; chemoradiotherapy; Hypoxia; IMRT; Intensity modulated radiotherapy; PET

Indexed keywords

18F-FMISO; CHEMORADIOTHERAPY; HYPOXIA; IMRT; INTENSITY-MODULATED RADIOTHERAPY; PET;

CHEMOTHERAPY; CONCURRENCY CONTROL; PATIENT MONITORING; PHYSICAL THERAPY; PLATINUM; POSITRONS; RADIOTHERAPY;

POSITRON EMISSION TOMOGRAPHY;

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; CARBOPLATIN; CISPLATIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; HEAD AND NECK CANCER; HUMAN; HYPOXIA; INTENSITY MODULATED RADIATION THERAPY; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; TUMOR VOLUME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CELL HYPOXIA; CISPLATIN; COMBINED MODALITY THERAPY; FLUOROURACIL; HUMANS; LARYNGEAL NEOPLASMS; MIDDLE AGED; MISONIDAZOLE; OROPHARYNGEAL NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED; TOMOGRAPHY, X-RAY COMPUTED; TUMOR BURDEN;

EID: 66149106936     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.10.049     Document Type: Article

References (57)

1. Brizel D.M., Sibley G.S., Prosnitz L.R., et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 38 (1997) 285-289
2. Bussink J., Kaanders J.H., and van der Kogel A.J. Tumor hypoxia at the micro-regional level: Clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. Radiother Oncol 67 (2003) 3-15
3. 2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 26 (1993) 45-50
4. Becker A., Hansgen G., Bloching M., et al. Oxygenation of squamous cell carcinoma of the head and neck: comparison of primary tumors, neck node metastases, and normal tissue. Int J Radiat Oncol Biol Phys 42 (1998) 35-41
5. Kaanders J.H., Wijffels K.I., Marres H.A., et al. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 62 (2002) 7066-7074
6. Brizel D.M., Dodge R.K., Clough R.W., et al. Oxygenation of head and neck cancer: Changes during radiotherapy and impact on treatment outcome. Radiother Oncol 53 (1999) 113-117
7. Nordsmark M., Bentzen S.M., Rudat V., et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy: An international multi-center study. Radiother Oncol 77 (2005) 18-24
8. Nordsmark M., and Overgaard J. A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiother Oncol 57 (2000) 39-43
9. Isa A.Y., Ward T.H., West C.M., et al. Hypoxia in head and neck cancer. Br J Radiol 79 (2006) 791-798
10. Corry J., and Rischin D. Strategies to overcome accelerated repopulation and hypoxia-What have we learned from clinical trials?. Semin Oncol 31 (2004) 802-808
11. Brown J.M., and Siim B.G. Hypoxia-specific cytotoxins in cancer therapy. Semin Radiat Oncol 6 (1996) 22-36
12. Dorie M.J., and Brown J.M. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res 53 (1993) 4633-4636
13. Dorie M.J., Menke D., and Brown J.M. Comparison of the enhancement of tumor responses to fractionated irradiation by SR 4233 (tirapazamine) and by nicotinamide with carbogen. Int J Radiat Oncol Biol Phys 28 (1994) 145-150
14. Rischin D., Peters L., Hicks R., et al. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol 19 (2001) 535-542
15. Rischin D., Hicks R.J., Fisher R., et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: A substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol 24 (2006) 2098-2104
16. Rischin D., Peters L., O'Sullivan B., et al. Phase III study of tirapazamine, cisplatin and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck. [Abstract]. J Clin Oncol 26 (2008)
17. Rischin D., Fisher R., Peters L., et al. Hypoxia in head and neck cancer: Studies with hypoxic positron emission tomography imaging and hypoxic cytotoxins. Int J Radiat Oncol Biol Phys 69 (2007) S61-S63
18. Brizel D.M., Rosner G.L., Harrelson J., et al. Pretreatment oxygenation profiles of human soft tissue sarcomas. Int J Radiat Oncol Biol Phys 30 (1994) 635-642
19. 2: A way of selecting patients for hyperoxic treatment. Strahlenther Onkol 172 Suppl. 2 (1996) 8-9
20. Apisarnthanarax S., and Chao K.S. Current imaging paradigms in radiation oncology. Radiat Res 163 (2005) 1-25
21. Bentzen L., Keiding S., Nordsmark M., et al. Tumour oxygenation assessed by 18F-fluoromisonidazole PET and polarographic needle electrodes in human soft tissue tumours. Radiother Oncol 67 (2003) 339-344
22. 18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 36 (1996) 417-428
23. Hicks R.J., Rischin D., Fisher R., et al. Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent. Eur J Nucl Med Mol Imaging 32 (2005) 1384-1391
24. Rajendran J.G., Schwartz D.L., O'Sullivan J., et al. Tumor hypoxia imaging with [F-18] fluromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res 12 (2006) 5435-5441
25. O'Donoghue J.A., Zanzonico P., Pugachev A., et al. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys 61 (2005) 1493-1502
26. Lee S.T., and Scott A.M. Hypoxia positron emission tomography imaging with 18F-fluoromisonidazole. Semin Nucl Med 37 (2007) 451-461
27. Lee N.Y., Mechalakos J.G., Nehmeh S., et al. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: A feasibility study. Int J Radiat Oncol Biol Phys 70 (2008) 2-13
28. Nehmeh S.A., Lee N.Y., Schroder H., et al. Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys 70 (2008) 235-242
29. Nakamoto Y., Osman M., Cohade C., et al. PET/CT: Comparison of quantitative tracer uptake between germanium and CT transmission attenuation-corrected images. J Nucl Med 43 (2002) 1137-1143
30. Nehmeh S., Hossam E.Z., Yusuf E., et al. An iterative technique for lesion segmentation in PET images. J Nucl Med 47 (2006) 364P
31. Soo K.C., Tan E.H., Wee J., et al. Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: A randomised comparison. Br J Cancer 93 (2005) 279-286
32. Pignon J.P., Bourhis J., Domenge C., et al. for the Meta-Analysis of Chemotherapy on Head and Neck Cancer (MACH-NC) Collaborative Group. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. Lancet 355 (2000) 949-955
33. Pignon J.P. le Maitre A, Bourhis J. Meta-Analyses of Chemotherapy in Head and Neck Cancer (MACH-NC): An update. Int J Radiat Oncol Biol Phys 69 (2007) S112-S114
34. de Arruda F.F., Puri D.R., Zhung J., et al. Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: The Memorial Sloan-Kettering Cancer Center experience. Int J Radiat Oncol Biol Phys 64 (2006) 363-373
35. Clark C.H., Miles E.A., Bidmead A.M., et al. In regard to Lee, et al., Int J Radiat Oncol Bio Phys 2002;53:630-637. Int J Radiat Oncol Biol Phys 55 (2003) 1150-1151
36. Barker Jr. J.L., Glisson B.S., Garden A.S., et al. Management of nonsinonasal neuroendocrine carcinomas of the head and neck. Head Neck 98 (2003) 2322-2328
37. Alber M., Paulsen F., Eschmann S.M., et al. On biologically conformal boost dose optimization. Phys Med Biol 48 (2003) N31-N35
38. Yao M., Karnell L.H., Funk G.F., et al. Health-related quality-of-life outcomes following IMRT versus conventional radiotherapy for oropharyngeal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 69 (2007) 1354-1360
39. Lee N.Y., de Arruda F.F., Puri D.R., et al. A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 66 (2006) 966-974
40. Senan S., Rampling R., Graham M.A., et al. Phase I and pharmacokinetic study of tirapazamine (SR 4233) administered every three weeks. Clin Cancer Res 3 (1997) 31-38
41. Rischin D., Peters L., Fisher R., et al. Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: A randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol 23 (2005) 79-87
42. von Pawel J., von Roemeling R., Gatzemeier U., et al. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group-Cisplatin and tirapazamine in subjects with advanced previously untreated non-small-cell lung tumors. J Clin Oncol 18 (2000) 1351-1359
43. Lee D.J., Trotti A., Spencer S., et al. Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: A phase II study. Int J Radiat Oncol Biol Phys 42 (1998) 811-815
44. Hall E. Radiobiology for the radiologist. 4th ed (1994), JB Lippincott, Philadelphia
45. Richmond R.C., Zimbrick J.D., and Hykes D.L. Radiation-induced DNA damage and lethality in E. coli as modified by the antitumor agent cis-dichlorodiammineplatinum (II). Radiat Res 71 (1977) 447-460
46. Korbelik M., and Skov K.A. Inactivation of hypoxic cells by cisplatin and radiation at clinically relevant doses. Radiat Res 119 (1989) 145-156
47. Skov K., and MacPhail S. Interaction of platinum drugs with clinically relevant x-ray doses in mammalian cells: A comparison of cisplatin, carboplatin, iproplatin, and tetraplatin. Int J Radiat Oncol Biol Phys 20 (1991) 221-225
48. Yan R.D., and Durand R.E. The response of hypoxic cells in SCCVII murine tumors to treatment with cisplatin and x rays. Int J Radiat Oncol Biol Phys 20 (1991) 271-274
49. Skov K.A., MacPhail H.S., and Marples B. The effect of radiosensitizers on the survival response of hypoxic mammalian cells: The low x-ray dose region, hypersensitivity and induced radioresistance. Radiat Res 138 (1994) S113-S116
50. Douple E.B., and Richmond R.C. Platinum complexes as radiosensitizers of hypoxic mammalian cells. Br J Cancer Suppl 3 (1978) 98-102
51. Gillison M.L. Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol 31 (2004) 744-754
52. Gillison M.L., Koch W.M., Capone R.B., et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92 (2000) 709-720
53. Gillison M.L., Koch W.M., and Shah K.V. Human papillomavirus in head and neck squamous cell carcinoma: Are some head and neck cancers a sexually transmitted disease?. Curr Opin Oncol 11 (1999) 191-199
54. Gillison M.L., and Lowy D.R. A causal role for human papillomavirus in head and neck cancer. Lancet 363 (2004) 1488-1489
55. Gillison M.L., and Shah K.V. Human papillomavirus-associated head and neck squamous cell carcinoma: Mounting evidence for an etiologic role for human papillomavirus in a subset of head and neck cancers. Curr Opin Oncol 13 (2001) 183-188
56. Fakhry C., and Gillison M.L. Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol 24 (2006) 2606-2611
57. Fakhry C., Westra W.H., Li S., et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100 (2008) 261-269